Clinical Trials Logo

Drug Resistant Epilepsy clinical trials

View clinical trials related to Drug Resistant Epilepsy.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06353620 Recruiting - Epilepsy Clinical Trials

Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy

Start date: February 13, 2024
Phase:
Study type: Observational

Recent studies have shown that the aperiodic part of the signal (neuronal avalanches) of electroencephalography (EEG) contains important information about the dynamics of neuronal networks. Indeed, this has helped to identify functionally altered areas in patients with temporal epilepsy by simply using the resting EEG signal. Furthermore, it has been seen that the propagation of neuronal avalanches (VNs) correlates with the morphological organization of the cerebral cortex. Therefore, NAs represent a measure with direct utility for studying functional reorganization pre and post drug/surgical treatment. In addition, the aperiodic portion of the signal may represent a noninvasive measure of the excitation/inhibition relationship, which is known of being altered both in epilepsy and in some rare neurodevelopmental syndromes (example: Angelman and Dup15q)

NCT ID: NCT06310954 Recruiting - Clinical trials for Epilepsy Intractable

Ketogenic Diet in Pediatric Intractable Epilepsy

Start date: August 11, 2022
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of a ketogenic diet in treating pediatric intractable epilepsy and to explore its relationship with changes in inflammatory markers. The investigators plan to recruit 59 participants with intractable epilepsy, 39 of whom will receive a combination of ketogenic diet and conventional antiepileptic drugs, while 20 will receive only conventional drugs. The study will assess the impact of the ketogenic diet on epilepsy control and inflammatory markers, hoping to discover new treatment strategies.

NCT ID: NCT06309251 Recruiting - Clinical trials for Autism Spectrum Disorder

Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients

Start date: March 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD. The main question[s] it aims to answer are: - does KD support adequate growth? - does KD improve clinical symptoms? - how does KD impact quality of life? Participants will be followed up as per clinical practice

NCT ID: NCT06304389 Recruiting - Refractory Epilepsy Clinical Trials

Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy

BLUELIGHTVNS
Start date: July 1, 2023
Phase: N/A
Study type: Interventional

Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response. Light, and particularly blue light, can stimulate alertness, attention and cognition through modulation of anatomical targets which are common to the vagal afferent network. This project aims at understanding how exposure to blue enriched light may influence VNS effects in patients with refractory epilepsy by exploring the modulation of a series of biomarkers of VNS action. This could possibly lead to new therapeutic strategies to increase efficacy of VNS.

NCT ID: NCT06292494 Recruiting - Clinical trials for Drug Resistant Epilepsy

Focused Ultrasound for Drug-resistant Epilepsy

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Focused ultrasound (FUS) has been shown to differentially lesion or modulate (excite and inhibit) brain circuit and neural activity across a broad range of acoustic stimulus parameters (intensity, duty cycle, pulse repetition frequency and pulse duration) for decades. From our previous study, FUS sonication may suppress the number of epileptic signal bursts observed in EEG recordings after the induction of acute epilepsy. The presence of the suppressive effect was found in terms of the number of epileptic EEG spikes from the analysis of the unfiltered and theta-band EEG activity, and further discontinue the seizure attacks. EEG activity has also been consistently reported to have a positive correlation with the level of epilepsy, and FUS-mediated reduction of epileptic EEG activity was most notably observed, no matter lesioning or modulating effects. The aims of this study are to demonstrate the safety and efficacy of FUS technology in epilepsy patients and to estimate the optimal parameters of focused ultrasound exposure that will be used in the case of epilepsy.

NCT ID: NCT06241963 Recruiting - Clinical trials for Transcranial Direct Current Stimulation

High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy

Start date: February 12, 2024
Phase: N/A
Study type: Interventional

To observe the clinical effect and safety of transcranial electrical stimulation on patients with refractory epilepsy before and after treatment and analyze its therapeutic mechanism.

NCT ID: NCT06212609 Recruiting - Epilepsy Clinical Trials

Optimized and Personalized Trans-cranial Brain Stimulation in Partial Refractory Epilepsies

PerEpi2
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Epilepsy is one of the most common neurological diseases, affecting between 0.5% and 1% of the general population. Therefore, new diagnostic and treatment methods are having a big impact on society. Epilepsy is also one of the most commonly diagnosed pediatric neurological disorders, with long-term implications for the quality of life of those affected and their relatives. In only two-thirds of cases, seizures can be adequately controlled with anticonvulsant drug therapy. For other patients with a drug-resistant focal epilepsy (up to around 2 million in Europe) epilepsy surgery is currently the most effective treatment. However, only 15-20% of these drug-resistant patients are eligible for epilepsy surgery. This is either because the cortical epileptogenic zone cannot be localized with sufficient precision with standard diagnostic means, or because the epileptogenic zone overlaps meaningful cortical areas, so that it cannot be surgically removed without considerable neurological deficit.

NCT ID: NCT06141668 Recruiting - Refractory Epilepsy Clinical Trials

Optimal Stimulation Parameters to Disrupt Epileptiform Activity

Start date: June 13, 2023
Phase: N/A
Study type: Interventional

Open-loop electrical stimulation has been found to reduce spike activity and seizures, but determining the optimal parameters to achieve these effects requires a brute force trial-and-error approach that relies on subjective physician discretion. We will compare the performance of stimulation parameters identified in rodent models to the recommended parameters for neuromodulation used in clinical practice.

NCT ID: NCT06075485 Recruiting - Clinical trials for Drug Resistant Epilepsy

Management of Drug-resistant Epilepsy in Infants and Children: a Real-life Study of the Use of the Ketogenic Diet in France and the KetoCal® Range in Its Maintenance

KEOPS
Start date: January 15, 2024
Phase:
Study type: Observational

This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and children up to 17 years of age (i.e. 18 years minus 1 day) with drug-resistant epilepsy. This study is being conducted according to standard medical practice. No change in diagnostic or therapeutic management habits is imposed by this study. Quality of life questionnaires are the only additional procedures for this research.

NCT ID: NCT06059157 Recruiting - Clinical trials for Drug Resistant Epilepsy

Epileptogenic Network Visualisation With Advanced MRI

EPIVAM
Start date: October 25, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to improve non-invasive identification of epileptogenic networks in drug-resistant epileptic patient. The investigators aim to compare epileptogenic network identification with stereo-EEG (used as glod standard) with the identification of the same network using advanced MRI (rs-fMRI, microstructural analysis of white matter, ...). The main goals are to: 1. Compare the accuracy of network identification. 2. Analyse the effect of the MRI sequences on candidates selection and target identification. Participants will already have been selected for stereoEEG and will undergo a supplementary MRI (about 1h) with the additional MRI sequences. Follow-up MRI are scheduled for patient undergoing a second, therapeutic epileptic surgery.